|
|
 |
|
Viewing report
|
|
|
|
Cancer Drug Blockbusters to 2016
Espicom Business Intelligence Ltd, Nov 2010, Pages: 170
Cancer Blockbusters to 2016 -The prospects and challenges for 21 US$1 billion oncology products
This new report’s glimpse into the future reveals a market environment where the new targeted therapies prevail as the future blockbusters, with biological, in particular, commanding substantial sales before the impact of any biosimilar competition in major markets.
The pursuit of safe and effective cancer medicines dominates research funding and the sector has more blockbuster products than any other therapy area.
There exists a huge variety of cancer treatments, from the widely-used chemotherapeutic agents to the recently-launched, first-in-class cancer vaccine, with many of these treatments achieving blockbuster sales in excess of US$1 billion. However, many existing brands face declining sales due to generic erosion as patents expire, and the rate at which new drugs reach the market is slowing, impacting company revenues.
This report identifies the current oncology blockbuster products and assesses their future market potential, looking at both winners and losers in the competitive landscape to 2016. In addition, it highlights the promising products that, in Espicom’s analysis, will successfully carve out a market share to become the oncology blockbusters of the future. Both current and future marketplaces are analysed from the companies’ perspective, identifying the products on which their relative success or failure rests.
All 21 products featured in this report are also detailed and analysed individually in terms of their current status, mode of action, clinical data, risks associated with their development, expertise of developing/marketing company and the competitive pressures they may face. This analysis is summarised in the form of a unique score that acts as a useful comparative tool and 7-year individual product forecasts are provided to 2016.
Whether you are involved with competitive monitoring, product planning or business development, this new report will provide the facts and insight to fully understand the trends, companies and products which are shaping this critical area of the pharmaceutical industry.
About this report:
- Comprehensive analysis of trends and impacts on companies: assess the winners and losers!
- An assessment of key therapeutic approaches – the rise of biologicals
- Detailed analysis of 21 products that will dominate the cancer market in the near term
- Detailed 7-year sales forecasts to 2016, with sales by indication where appropriate
Answering key questions:
- Which companies will have increased their market share by 2016?
- Who will be the new members of the cancer blockbuster club in the future?
- What are the prospects for hormonal therapies?
- To what degree will Sprycel, Tasigna and generic competition affect Novartis’ Gleevec?
- What product extensions did Roche get for Herceptin in 2010?
- Where to next for Pfizer after it suspended development of Sutent in a range of cancers in September 2009?
- How might cheaper generic doxetaxel affect sales of Dendreon’s novel vaccine for CRPC patients?
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Breast Cancer Drug Futures 2010
Colorectal Cancer Drug Futures 2010
Lung Cancer Drug Futures 2010
Multiple Sclerosis Drug Discoveries - What the Future Holds
Prostate Cancer Drug Futures 2010
Renal Cell Carcinoma Cancer Drug Futures 2010
Threats to Avastin - Targeting the VEGF Pathway
MRSA Drug Futures
Ophthalmology Drug Futures: Sight Preservation in Chronic Eye Diseases
Will Anyone Crack the Obesity Drug Market?
|
|
|
|
